UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 333-258582 CIRCLE INTERNET GROUP, INC. (State or other jurisdiction of incorporation or organization) Delaware 99-2840247 (I.R.S. Employe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42383 OAKTREE ACQUISITION CORP. III LIFE SCIENCES (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 98 ...

Table of Contents Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42383 OAKTREE ACQUISITION CORP. III LIFE SCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 98 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-41778 LQR House Inc. (Exact name of registrant as specified in its charter) Nevada 86-1604197 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-38308 Greenpro Capital Corp. (Exact name of registrant issuer as specified in its charter) Nevada 98-1146821 (State or o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38410 BioXcel Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1386754 (S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-42398 LIFEWAY FOODS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41315 John Marshall Bancorp, Inc. (Exact name of registrant as specified in its charter) Virginia 81-5424879 ( ...

[Business and Operational Highlights](index=1&type=section&id=Business%20and%20Operational%20Highlights) The company achieved record Q2 2025 performance, capitalizing on consumer wellness trends and reinforcing its kefir market leadership - Lifeway was named **Processor of the Year** by Dairy Foods magazine, the publication's highest annual honor, recognizing the Company's innovation and leadership[3](index=3&type=chunk) - The company is capitalizing on powerful consumer tailwinds, including the wellness boom and the surge in **GLP-1 medication use**, by offering nutrient-dense, protein-rich, probiotic foods[2](index=2&type=chunk) [Q3 2025 Momentum and Outlook](index=1&type=section&id=Q3%202025%20Momentum%20and%20Outlook) The company reports strong sales momentum entering Q3 and reiterates its long-term financial targets for 2027 - Unaudited net sales for Q3 to date reached **$26.4 million**, an increase of more than **20%** year-over-year[1](index=1&type=chunk)[5](index=5&type=chunk) - In July, Lifeway recorded the **highest single week of gross sales** in Company history, surpassing **$5.5 million**[5](index=5&type=chunk) - The Company reiterated its long-term target of **$45–$50 million in Adjusted EBITDA for FY 2027** and expects record annual sales in 2025[7](index=7&type=chunk) [Growth Trends and Innovation](index=1&type=section&id=Growth%20Trends%20and%20Innovation) The company's innovative collagen-infused smoothies are capitalizing on the growing 'beauty from within' trend - Lifeway's Probiotic Smoothies with Collagen are resonating with consumers, tapping into the rapidly growing **$8 billion global market for collagen**[4](index=4&type=chunk) - The Berry Blast flavor of the collagen smoothie won a **2025 Good Housekeeping Snack Award**, highlighting the product's success and consumer appeal[4](index=4&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Performance) The company delivered record Q2 2025 net sales with expanded gross profit margin and net income growth Q2 2025 Key Financial Metrics | Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Net Sales | $53.9M | $49.2M | +9.7% | | Gross Profit Margin | 28.6% | 27.0% | +160 bps | | Net Income | $4.2M | $3.8M | +10.5% | | Diluted EPS | $0.28 | $0.25 | +12.0% | [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Net sales grew 9.7% in Q2 2025, driving higher gross profit and net income despite increased operating expenses Three Months Ended June 30 (in thousands) | Account | 2025 | 2024 | | :--- | :--- | :--- | | Net sales | $53,901 | $49,157 | | Gross profit | $15,400 | $13,275 | | Income from operations | $5,795 | $5,386 | | Net income | $4,249 | $3,783 | | Diluted EPS | $0.28 | $0.25 | Six Months Ended June 30 (in thousands) | Account | 2025 | 2024 | | :--- | :--- | :--- | | Net sales | $99,992 | $93,791 | | Gross profit | $26,435 | $24,810 | | Income from operations | $7,369 | $8,950 | | Net income | $7,789 | $6,209 | [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) Total assets and stockholders' equity increased, driven by a significant rise in cash and cash equivalents Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $21,220 | $16,728 | | Total current assets | $49,331 | $43,605 | | Total assets | $98,267 | $90,547 | | Total current liabilities | $16,289 | $15,504 | | Total liabilities | $19,571 | $18,636 | | Total stockholders' equity | $78,696 | $71,911 | [Consolidated Statements of Cash Flows](index=6&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash increased by $4.5 million, supported by strong proceeds from investing activities despite lower operating cash flow Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $3,762 | $8,090 | | Net cash provided by (used in) investing activities | $795 | $(3,905) | | Net cash used in financing activities | $(65) | $(2,750) | | **Net increase in cash** | **$4,492** | **$1,435** | [Other Information](index=2&type=section&id=Other%20Information) This section details the non-GAAP financial measure Adjusted EBITDA and outlines forward-looking statement risks [Non-GAAP Financial Measures](index=2&type=section&id=Non-GAAP%20Financial%20Measures) The company utilizes the non-GAAP measure Adjusted EBITDA for its outlook and cannot reconcile it to GAAP net income - **Adjusted EBITDA** is a non-GAAP measure defined as Operating Income, as reported, plus Depreciation and Amortization, plus Stock-Based Compensation[7](index=7&type=chunk)[11](index=11&type=chunk) - The Company cannot reconcile its target fiscal year **2027 Adjusted EBITDA** to projected net income without unreasonable effort due to uncertainty[12](index=12&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) The report contains forward-looking statements subject to risks including competition, pricing, and an unsolicited acquisition proposal - The press release contains **forward-looking statements** that are subject to risks and uncertainties beyond the company's control[10](index=10&type=chunk) - Identified risks include price competition, commodity pricing, and uncertainty related to an **unsolicited acquisition proposal from Danone**[10](index=10&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-39403 Abacus Global Management, Inc. (Exact name of registrant as specified in its charter) Delawar ...